Ambuja Cements Regulatory Approval

Acquisition

Ambuja Cements Acquisition Worth ₹33.75 Cr

Ambuja Cements will acquire 26% of SWE Renewables for ₹33.75 Crore over 15 months. The move targets wind-powered captive electricity to reduce grid dependence.

Value

₹33.75 Cr

Execution

15 months (in one or more tranches)

Earnings Call

Ambuja Cements Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹9,197 Cr, flat YoY. EBITDA ₹1,271 Cr (-28%), margin 13.8% (vs 19.2%). Reported PAT ₹236 Cr (-90%). Company remains debt-free.

Results Update

Ambuja Cements Results Update

Ambuja Cements posted Q2 FY27 consolidated revenue of Rs 9,197 Cr with EBITDA of Rs 1,271 Cr. The firm commissioned 4.6 MTPA of new capacity amid headwinds.

cement manufacturing capacity

4.6 MTPA

Financial Results

Ambuja Cements Q2 FY27 Results: Net Profit ₹236 Cr, Down 89.9% YoY

Ambuja Cements Ltd reported revenue from operations of ₹9,197 Cr (+0.2% YoY) and net profit of ₹236 Cr (-89.9% YoY) for Q2 FY27.

Key figure

Net profit ₹236 Cr · -89.9% YoY

Share Pledge

Ambuja Cements Share Pledge

Ambuja Cements' promoters reported a share encumbrance involving a facility of USD 1.375 billion, equivalent to approximately 13,062.50 Crore. This is a promoter encumbrance disclosure.

Value

₹13,062 Cr

Share Pledge

Ambuja Cements Share Pledge

Deutsche Bank disclosed under SAST Regulation 29(2) an extended encumbrance over 66.94% of Ambuja Cements shares. The charge secures a new facility to Endeavour, with no change in the number of encumbered shares.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.